From Barchart: 2024-12-10 02:48:00

Jefferies initiated Quest Diagnostics (NYSE:DGX) with a Buy rating and $185 price target, citing growth potential from strategic pricing, new contracts, and industry consolidation. Revenue is expected to surpass pre-pandemic levels, driven by recent contracts with Elevance and Sentara Health. The company’s valuation at 11.5x EBITDA reflects a 24% discount to the S&P 500, with growth opportunities in oncology diagnostics and regional expansion through acquisitions like LifeLabs. Mergers and acquisitions are projected to contribute over 2% annual growth through 2026, positioning Quest Diagnostics for upward revaluation and significant growth in the future.



Read more at Barchart:: Jefferies Sees Upside Potential for Quest Diagnost…